Objective
The major objective of this proposal is to develop a new generation of safe and effective bacterial live carriers which are suitable for oral vaccination. To achieve this overall objective a multi-disciplinary collaboration has been set up between four academic institutes and one European vaccine company. In the proposed project all partners are dedicated to assess systematically the potential of attenuated Brucella, Salmonella and Yersinia strains to protect against infectious diseases. Vaccine induced protection often depends on the ability to elicit immune responses against a specific peptide or epitope in a fashion that mimics natural infection. The possibility of delivering an antigen into different processing and presentation pathways promises to be a powerful tool for designing vaccines. In this study a major immunogen of Listeria monocytogens, the p60 protein, will serve as a model antigen that has to be delivered by the different bacterial live carrier. By genetic manipulation of microorganisms and the use of different bacterial secretion systems the p60 antigen will be specifically targeted into either the extracellular, endosomal or cytoplasmic compartment of infected cells. Consequently, different branches of the immune response are expected to be stimulated: Extracellular antigens are known to be eliminated by antibodies, whereas cytosolic antigens are presented to CD8 T-cells via the MHC class I pathway.
Antigens derived from endosomal compartments are processed by the MHC class 11 pathway and recognized by CD4 T-cells. Within the scope of this project the newly designed carrier expressing the p60 antigen will be used for in-vitro and in vivo experiments to determine antibody responses, cytokine profiles and T-cell subsets subsequent to infection of various tissue culture cell lines or mice. CD4 and CD8 epitope-deleted p60 proteins will serve as negative controls in assays where cellular immune responses are measured.
Ultimately, the different bacterial live carrier will be compared with respect to the efficacy of protection against listeriosis in a mouse model of infection.
The combined efforts of all partners with highly complementary expertise will allow the development of a new generation of effective and safe bacterial live vaccine carriers for a wide range of infectious diseases.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences infectious diseases
- medical and health sciences medical biotechnology genetic engineering
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine immunology
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
80336 München
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.